C. Difficile

Clinical trial pipeline · Data from ClinicalTrials.gov

See which C. Difficile trials you may qualify for

100

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

RecruitingPhase 2

NCT07285213

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18…

United States230 participantsStarted 2025-12-10

Treatment: AZD5148, Placebo

RecruitingPhase 3

NCT07328971

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10…

Canada500 participantsStarted 2026-04-24

Treatment: Fidaxomicin, Vancomycin capsule

RecruitingPhase 3

NCT06237452

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in partic…

United States852 participantsStarted 2024-05-20

Treatment: VE303, Placebo

RecruitingNot Applicable

NCT05389904

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

Clostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US.…

United States300 participantsStarted 2022-07-25

Treatment: Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle

RecruitingPhase 2/3

NCT05330182

LMN-201 for Prevention of C. Difficile Infection Recurrence

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive…

United States375 participantsStarted 2024-08-29

Treatment: LMN-201, Placebo

RecruitingNot Applicable

NCT07250724

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of thi…

United States60 participantsStarted 2026-02-01

Treatment: Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.

All recent trials (100 shown)

Active — Not RecruitingPhase 1/2

NCT05805826

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarr…

United States936 participantsStarted 2023-03-23

Treatment: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1.

Not Yet RecruitingNot Applicable

NCT06992453

Multi-omics Dissection of Gut Microbiome Engraftment During FMT

The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (…

Italy90 participantsStarted 2026-04-23

Treatment: Fecal microbiota transplantation (FMT)

C. Difficile

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

LMN-201 for Prevention of C. Difficile Infection Recurrence

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

All recent trials (100 shown)

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

Multi-omics Dissection of Gut Microbiome Engraftment During FMT

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

LMN-201 for Prevention of C. Difficile Infection Recurrence

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

All recent trials (100 shown)

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

Multi-omics Dissection of Gut Microbiome Engraftment During FMT

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy…

Fecal Microbiome Transplant

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Di…

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery

InPART RX - Epicenters

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

C.Difficile Observational Study

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bo…

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

Support of Colonization Resistance of the Gut Microbiota with the Synbiotic Food Supplement Nagasin®

FQ Restriction for the Prevention of CDI